Grant: Engage Grants Program
University of Waterloo
$25,000.00
Improving protein production using an integrative metabolomic/ trace element analysis approach
FY 2011-12
Summary
Therapeutic protein manufacturing is an extremely competitive, billion dollar industry that is targeted towards
improving health and lifestyle. Therapure Biopharma Inc. (TBI) is a Canadian-based biopharmaceutical
company committed to the development, manufacture, purification, and packaging of rare and complex
biotherapeutics. In Canada, TBI is the only Contract Development and Manufacturing Organization (CDMO)
that has remained viable for protein production in animal cells, helping to develop and manufacture
therapeutics for biopharmaceutical companies of all sizes including virtual biotech companies to
multinationals. To remain competitive,TBI is looking to gain additional insight on their production processes -
namely their cell culture platforms - in order to streamline their production cycle, and enable a broader range of
product offerings at more competitive costs. This proposal is to support a new collaborative effort between the
Aucoin Lab at the University of Waterloo and TBI for the characterization of cells and their growth media
using a metabolomics approach based on nuclear magnetic resonance (NMR) and inductively-coupled mass
spectrometry (ICP-MS) analysis. While conventional methods for characterizing organic metabolites have
focussed too simply on amino acids, glucose, lactate and ammonia, this work will examine a much broader
array of components to elucidate differences among the requirements for producing different products at
different levels. Ultimately, it is the aim of this collaborative effort to develop an in-house media formulation
that will increase the robustness of TBI and reduce the need to rely on external suppliers for this critical aspect
of their process.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
413645-2011
Name nom
Aucoin, Marc
Department département
Chemical Engineering
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2011
Award amount
25000
Program id
EGP
Program nane en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
1
Nb partie
1
Application title
Improving protein production using an integrative metabolomic/ trace element analysis approach
Keyword
NSERC
Application summary
Therapeutic protein manufacturing is an extremely competitive, billion dollar industry that is targeted towards
improving health and lifestyle. Therapure Biopharma Inc. (TBI) is a Canadian-based biopharmaceutical
company committed to the development, manufacture, purification, and packaging of rare and complex
biotherapeutics. In Canada, TBI is the only Contract Development and Manufacturing Organization (CDMO)
that has remained viable for protein production in animal cells, helping to develop and manufacture
therapeutics for biopharmaceutical companies of all sizes including virtual biotech companies to
multinationals. To remain competitive,TBI is looking to gain additional insight on their production processes -
namely their cell culture platforms - in order to streamline their production cycle, and enable a broader range of
product offerings at more competitive costs. This proposal is to support a new collaborative effort between the
Aucoin Lab at the University of Waterloo and TBI for the characterization of cells and their growth media
using a metabolomics approach based on nuclear magnetic resonance (NMR) and inductively-coupled mass
spectrometry (ICP-MS) analysis. While conventional methods for characterizing organic metabolites have
focussed too simply on amino acids, glucose, lactate and ammonia, this work will examine a much broader
array of components to elucidate differences among the requirements for producing different products at
different levels. Ultimately, it is the aim of this collaborative effort to develop an in-house media formulation
that will increase the robustness of TBI and reduce the need to rely on external suppliers for this critical aspect
of their process.